Professor A. Vahanian (Paris, FR)
Professor J. Bax (Leiden, NL)
Doctor M. Sitges (Barcelona, ES)
Doctor F. Praz (Bern, CH)
After watching this webinar, participants will understand:
why it is important to identify tricuspid regurgitation and how to diagnose, evaluate, and treat it;
the body of evidence supporting therapy value with a focus on clinical outcomes;
which patients can benefit from transcatheter tricuspid valve repair; and
how to evaluate the tricuspid valve (echo screening guidance) and how to define patient echo eligibility.
Needs assessment and expected educational outcome:
To understand expanding transcatheter treatment options for patients suffering from tricuspid regurgitation by reviewing clinical outcomes from the TRILUMINATE trial and by delving into real-world data of the TriClip bRIGHT Study documenting repairs using the Abbott TriClip device. This body of evidence is mentioned in the 2020 ACC Guidelines and in the new 2021 ESC/EACTS/HF Guidelines.
This programme is supported by Abbott in the form of an educational grant. The scientific programme has not been influenced in any way by its sponsor.